Phosplatin Therapeutics LLC has finished dosing patients from its phase I first-in-human clinical study of PT-112, the company’s lead therapeutic candidate within their phosphaplatin family of molecules.
The study will take place with the collaboration of three facilities, including The University of Texas MD Anderson Cancer Center in Houston, Texas.
PT-112 is a novel molecule, first synthesized by the chairman of the Phosplatin Therapeutics Scientific Advisory Board, Rathindra N. Bose, PhD, and continues in line with the company’s goal of developing phosphaplatins, a novel class of chemotherapeutic compounds.
The company expects to enroll up to 80 solid tumour cancer patients on the PT-112 study, at the Sarah Cannon Research Institute in Nashville, Tennessee, and the University of Colorado Cancer Center in Aurora, Colorado, in addition to the UT MD Anderson Cancer Center.
“The platinum family of chemotherapies has been a bedrock contributor to long-term survival of cancer patients, and remains so today, even in our world of targeted therapies,” principal investigator Daniel Karp, M.D., who is a professor of investigational cancer therapeutics, and medical director of the Clinical Translational Research Center at MD Anderson said in a press release. “We are delighted to be involved in this important study of PT-112.”
The company expects PT-112 to become a unique electrochemistry and plasma stability treatment, more tolerable and safer than prior members of the platinum therapeutic class in pre-clinical studies. It has already been proved efficient in previous studies conducted with mouse models and patient-derived tumors.
During the first part of the study, the research team will administrate a dose escalation portion to patients in order to evaluate the safety, pharmacokinetic behaviour and maximum tolerated dose of PT-112 in an open label setting. In the second part of the study, researchers will confirm the portion of PT-112 that is adequate within discreet cohorts of patients with specific disease characteristics.
“For a small company like ours it is both encouraging, and testimony to the therapeutic potential of our compound, that we have been able to line up a top-tier group of clinical sites and investigators to lead the first trial of PT-112 in humans,” commented Phosplatin Therapeutics’s CEO, Robert E. Fallon.